% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • elstockjock elstockjock Jun 14, 2013 2:19 AM Flag

    TSRX is a buyout candidate!

    Pharmaceuticals (CBST) might be interested in acquiring Trius because it would solve it's problem with daptomycin resistance and also extend the market exclusivity of daptomycin to beyond 2017. I agree with Jason when he says, "We believe investors should pay up to $12 per share for Trius -- Cubist could pay a whole lot more." With sales of daptomycin expected to reach about $1 Billion for Cubist Pharmaceuticals in 2013, it would make sense that they would want to extend their exclusivity period and increase its efficacy.

    Trius could represent an opportunity for investors to capitalize on a potential buyout or partnership deal.

    Buy out price target opinion: $15-$17

    SortNewest  |  Oldest  |  Most Replied Expand all replies